SCHEMBL6706099

SCHEMBL6706099

Cc1ccc(/C(C#N)=N\O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 11/20 0.40
LMNA P02545 6/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
MAPT P10636 6/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CYP2A6 P11509 1/20 0.39
HTT P42858 4/20 0.37
HIF1A Q16665 1/20 0.37
GAA P10253 2/20 0.36
ALOX12 P18054 1/20 0.36
TDP1 Q9NUW8 4/20 0.35
PKM P14618 2/20 0.35
ATM Q13315 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706101 1.00 HSD17B10 (0.46) HSD17B10TP53ALDH1A1LMNASMN1; SMN2
SCHEMBL10753245 1.00 HSD17B10 (0.46) HSD17B10TP53ALDH1A1LMNASMN1; SMN2
SCHEMBL8594589 0.81 MAOB (0.56) ALDH1A1LMNASMN1; SMN2MAPTNPC1
SCHEMBL8594586 0.81 MAOB (0.56) ALDH1A1LMNASMN1; SMN2MAPTNPC1
SCHEMBL10752086 0.78 TSHR (0.43) HSD17B10ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL7561533 0.78 RECQL (0.42) HSD17B10ALDH1A1LMNAMAPTCES2
SCHEMBL7561536 0.78 RECQL (0.42) HSD17B10ALDH1A1LMNAMAPTCES2
SCHEMBL22347726 0.78 RECQL (0.42) HSD17B10ALDH1A1LMNAMAPTCES2
SCHEMBL10752089 0.78 TSHR (0.43) HSD17B10ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL11320370 0.78 TSHR (0.43) HSD17B10ALDH1A1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770420-B2 Alkylsulfonyloximes for high-resolution i-line photoresists of high sensitivity CIBA SPECIALTY CHEMICALS CORPORATION 2004-08-03 US disclosed
US-20040013974-A1 Alkylsulfonyloximes for high-resolution i-line photoresists of high sensitivity DIETLIKER KURT (CH) 2004-01-22 US disclosed
EP-0925529-B1 ALKYSULFONYLOXIMES FOR HIGH-RESOLUTION I-LINE PHOTORESISTS OF HIGH SENSITIVITY CIBA SC HOLDING AG (CH) 2003-04-16 EP disclosed
EP-0925529-A1 ALKYSULFONYLOXIMES FOR HIGH-RESOLUTION I-LINE PHOTORESISTS OF HIGH SENSITIVITY Ciba SC Holding AG (CH) 1999-06-30 EP disclosed
WO-1998010335-A1 ALKYSULFONYLOXIMES FOR HIGH-RESOLUTION I-LINE PHOTORESISTS OF HIGH SENSITIVITY CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-03-12 WO disclosed
EP-0426460-A1 Oxime ether derivative, preparation thereof and germicide containing the same UBE INDUSTRIES, LTD. (JP) 1991-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040013974-A1 Alkylsulfonyloximes for high-resolution i-line photoresists of high sensitivity SULT1E1, CCNT1, CCNE1 HSD17B10 2497/4885TP53 4717/4885ALDH1A1 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.